211 results about "Staphylococcus albus" patented technology

The invention belongs to the technical field of antibacterial drugs, and discloses a coumarin thioether pleuromutilin derivative and application thereof.The coumarin thioether pleuromutilin derivative is a compound with the structure shown in the formula I and pharmaceutically acceptable salt of the compound, and in the formula, R1 and R2 are H, OMe, NO2, NH2, Me, F, Cl or Br. The antibacterial agent is novel in structure and has excellent antibacterial activity. In-vitro antibacterial experiment results show that all the compounds have antibacterial effects superior to that of tiamulin, most of the compounds have antibacterial effects equivalent to that of control valnemulin, and the compound has a significant effect on five gram-positive bacteria staphylococcus aureus drug-resistant strains ATCC 33591 and ATCC 43300, staphylococcus aureus sensitive strains ATCC 2913, staphylococcus epidermidis drug-resistant strains ATCC 51625, staphylococcus epidermidis sensitive strains ATCC 12228, staphylococcus aureus drug-resistant strains ATCC 51625, staphylococcus aureus sensitive strains ATCC 12228, staphylococcus aureus drug-resistant strains ATCC 51625 and staphylococcus aureus sensitive strains ATCC 12228. Wherein the bacteriostatic activities of the nine compounds are less than or equal to 0.062 mu g.mL <-1 >. The compound is expected to be applied to treatment of bacterial infection caused by staphylococcus aureus, and a new choice is provided for anti-infection drugs.

The invention is applicable to the technical field of polypeptides, and provides a novel antibacterial peptide GG25 and application thereof, and the amino acid sequence of the antibacterial peptide GG25 is as shown in SEQ ID No.1. The molecular weight of the novel antibacterial peptide GG25 is 2890.52 Da, and the novel antibacterial peptide GG25 has antibacterial activity on escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, enterococcus faecalis, salmonella typhimurium, methicillin-resistant staphylococcus aureus, staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes and bacillus subtilis; the hemolytic activity is low, the cytotoxicity is small, and the escherichia coli and methicillin-resistant staphylococcus aureus are not easily induced to generate drug resistance; in addition, the gelatin chitosan food coating containing GG25 also has a good beef preservation effect, and can be applied to the fields of food, animal husbandry, medicine and the like.

The invention relates to Penicillium decumbens C01 and application of the Penicillium decumbens C01, and belongs to the technical field of microorganisms. The penicillium decumbens C01 disclosed by the invention is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the penicillium decumbens C01 is GDMCC NO.66456. The strain is obtained by separating, purifying and screening soil samples collected from botanical gardens in South China of Guangzhou; tests show that the bacteriostatic active substance generated by fermentation of the strain has a good bacteriostatic effect on staphylococcus epidermidis, staphylococcus aureus, escherichia coli, propionibacterium acnes, candida albicans and pseudomonas aeruginosa, and the bacteriostatic active substance has the characteristic of high temperature resistance and excellent preservative effect; the antibacterial preservative can be used as an antibacterial preservative raw material, is applied to the fields of food, health care products or daily chemical products and the like, and has wide application prospects and important conversion research values.

The invention relates to a composite amplification detection system for identifying human skin based on microbial markers. The multiplex amplification detection system comprises a primer combination for specifically amplifying five human skin microorganism markers, wherein the human skin microorganism markers are staphylococcus epidermidis, staphylococcus hominis, staphylococcus capitis, staphylococcus aureus and propionibacterium acnes respectively. The invention also provides a kit containing the composite amplification detection system. The multiplex amplification detection system and the kit have relatively good recognition capability on skin of parts such as forehead, cheeks, hands, chest, navel periphery and groin of a human body. Besides, the method is an effective supplement for an existing body fluid identification method, and can effectively identify various common body fluid samples in forensic cases by flexibly combining with a multiple amplification system for saliva and vaginal secretion established by a previous team, so that the accuracy and reliability of identification results are improved, and case investigation and judicial trial are assisted.

The invention discloses an application of a small molecule compound DK419 in preparation of a drug for resisting staphylococcus infection, and the CAS number of the small molecule compound DK419 is 2102672-22-8; the staphylococcus comprises at least one of staphylococcus aureus, staphylococcus epidermidis, staphylococcus hominis, staphylococcus capitis and staphylococcus haemolyticus. According to the technical scheme, the novel medical application of DK419 is disclosed, DK419 has the effects of inhibiting growth of staphylococcus and killing staphylococcus aureus, the antibacterial effect is better than that of first-line antibiotic vancomycin, and the bactericidal effect is equal to that of vancomycin; the DK419 has the effect of efficiently removing a biofilm; the DK419 can play a role in resisting staphylococcus aureus infection in an in-vivo skin infection model.

The invention belongs to the technical field of polypeptide drugs in biochemistry, and discloses three antibacterial peptide analogues as well as a preparation method and application thereof, the sequence of an antibacterial peptide P-1 is CH3CO-GGGENIKKILSKIKLLK-NH2, the sequence of an antibacterial peptide P-2 is CH3CH2CH2CO-GGGENIKKILSKIKLLK-NH2, the sequence of an antibacterial peptide P-3 is CH3 (CH2) 6CO-GGGENIKKILSKIKLLK-NH2, the carboxyl ends of polypeptides are subjected to amidation, and the polypeptides are all positively charged when the pH is equal to 7. The artificially synthesized antibacterial peptide disclosed by the invention shows a remarkable sterilization effect on multidrug resistant staphylococcus epidermidis. P-1, P-2 and P-3 have small molecular weight, are convenient to synthesize, have broad-spectrum bactericidal activity, are self-assembled into nanoparticles, have low cytotoxicity, resist trypsin degradation and the like, and have wide application prospects.

The invention discloses glucoside hydrolase with anti-biofilm activity and application of the glucoside hydrolase. Experiments prove that the PgaBAb1 protein and the PgaBKp protein have remarkable anti-staphylococcus epidermidis biofilm activity and can destroy a mature staphylococcus epidermidis biofilm and inhibit formation of the staphylococcus epidermidis biofilm, that is, the PgaBAb1 protein and the PgaBKp protein are glucoside hydrolase with anti-biofilm activity; meanwhile, the sensitivity of the staphylococcus epidermidis to methicillin can be improved; the amino acid sequences of the PgaBAb1 protein and the PgaBKp protein are respectively as shown in SEQ ID NO: 5 and SEQ ID NO: 6. Therefore, both the PgaBAb1 protein and the PgaBKp protein can be used as active ingredients of drugs to treat diseases caused by infection of bacteria generating biological membranes and / or drug-resistant bacteria. The method has an important application value.

The invention discloses a breast milk-derived staphylococcus epidermidis strain and application thereof. The invention provides a staphylococcus epidermidis strain, and the preservation number of the staphylococcus epidermidis strain is CGMCC (China General Microbiological Culture Collection Center) No.31507. The staphylococcus epidermidis strain has the advantages that the staphylococcus epidermidis strain can be used for preparing the staphylococcus epidermidis strain; the strain of the staphylococcus epidermidis, provided by the invention, has good intestinal adaptive capacity, safety and stability, and can be used for inhibiting enteropathogenic bacteria and improving the immune response reaction of host immune cells.

The invention discloses a cytochalasin compound with wide antibacterial activity as well as a preparation method and application thereof. According to the present invention, the cytochalasin polymer is obtained by separation from the fermentation product derived from the Aspergillus izzukae (Aspergillus izzukae), such that the cytochalasin polymer can be obtained, the preservation number of the Aspergillus izzukae PJ03-11 is CGMCC (China General Microbiological Culture Collection Center) No.40601, and the preservation number of the Aspergillus izzukae PJ03-11 is CGMCC No.40601. The compound has a structure of a cytochalasin mother nucleus and an epiccine mother nucleus, and shows good activity in the aspects of inhibiting or killing staphylococcus aureus, methicillin-resistant staphylococcus aureus, multidrug-resistant staphylococcus aureus, streptococcus pneumoniae, staphylococcus epidermidis and vancomycin-resistant enterococcus faecalis; the compound can be used for preparing novel agricultural or medical antibacterial drugs.

The invention discloses an application of a milk peptide fermentation product in regulating skin micro-ecological balance, and belongs to the technical field of biological fermentation application, and the milk peptide fermentation product selectively regulates and controls the growth of staphylococcus epidermidis and inhibits the growth of staphylococcus aureus and escherichia coli. The milk peptide leavening is found to have a selective bacteriostatic effect on skin microorganisms for the first time, experimental results show that the milk peptide leavening has an inhibiting effect on escherichia coli and staphylococcus aureus, but has no influence on normal growth of epidermis grape germs, and the characteristic is obviously different from that of a common broad-spectrum chemical bacteriostatic agent; the milk peptide leavening is more beneficial to maintenance of skin flora balance.

The invention belongs to the technical field of microorganisms, and particularly relates to a staphylococcus epidermidis H62-3 metabolite gel preparation as well as a preparation method and application thereof. The staphylococcus epidermidis H62-3 metabolite gel preparation improves skin erythema and scale symptoms of a psoriasis mouse model, remarkably reduces the skin lesion thickness, can reduce the mRNA expression level of inflammatory factors interleukin-17A, interleukin-17F and interleukin-23 at the skin lesion of the psoriasis mouse model, and can be used for treating psoriasis. The compound has a prospect of being developed into drugs for treating inflammatory dermatosis. The staphylococcus epidermidis H62-3 metabolite gel preparation disclosed by the invention is used for improving a psoriasis mouse model, and a new thought for safely and effectively treating inflammatory skin diseases by external use of viable bacteria metabolite is provided.

The invention belongs to the technical field of microorganisms, and particularly relates to application of a staphylococcus epidermidis H62-3 viable bacterium preparation in preparation of a medicine for preventing or treating psoriasis. Experimental results show that the staphylococcus epidermidis H62-3 viable bacterium preparation improves skin erythema and scale symptoms of a psoriasis mouse model, remarkably reduces the skin lesion thickness, reduces the mRNA expression level of cytokines related to psoriasis at the skin lesion position of the psoriasis mouse model, and improves the psoriasis resistance of the psoriasis mouse model. And the cell factors comprise interleukin-17A, interleukin-17F and interleukin-23. The invention also discloses a preparation method of the cell factor. Therefore, the staphylococcus epidermidis H62-3 viable bacterium preparation has the prospect of being developed into the medicine for preventing or treating psoriasis.

The present application relates to a strain of Penicillium decumbens (P. Penicillium decumbens ) C01 and its application, and belongs to the field of microbial technology. The Penicillium decumbens C01 disclosed by the present application has been preserved in the Guangdong Microbial Digital Culture Collection Center, and its preservation number is GDMCC NO.66456. The strain is isolated, purified and screened from a soil sample collected in the garden area of Guangzhou South China Botanical Garden. Tests show that the bacteriostatic active substance produced by fermentation of the strain has good bacteriostatic effect on Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Propionibacterium acnes, Candida albicans and Pseudomonas aeruginosa. Moreover, the bacteriostatic active substance has high-temperature resistance and excellent preservative effect, and can be used as a bacteriostatic and preservative raw material, applied in the fields of food, health care products or daily chemical products, and has broad application prospect and important transformation research value.

The invention discloses a mild antibacterial anti-dandruff composition and a preparation method thereof. The composition comprises an acrylate copolymer, maltooligosaccharide and bisabolol, the mass ratio of the acrylate copolymer to the maltooligosaccharide to the bisabolol is (0.01 to 0.3) to (0.1 to 0.8) to (0.05 to 0.5); the preparation method comprises the following steps: sequentially adding the acrylate copolymer, the maltooligosaccharide and the bisabolol into water according to the mass ratio, and uniformly stirring until the materials are dissolved. The acrylate copolymer, the maltooligosaccharide and the bisabolol are blended in proportion, the maltooligosaccharide becomes a carbon source of microorganisms, malassezia is efficiently inhibited, staphylococcus epidermidis is not excessively inhibited, and meanwhile, the skin mildness and moisture retention are achieved; the bisabolol is used as a plasticizer, so that the composition of the acrylate copolymer and the maltooligosaccharide forms a uniform and tough film, the effect on malassezia and staphylococcus epidermidis is enhanced, and the anti-dandruff effect is improved.

The application discloses a fabric yellowing reagent and a fabric yellowing method, and relates to the technical field of daily chemical products. 5 The fabric yellowing reagent comprises 1-3% of histidine solution and a bacterial suspension with a bacterial concentration of 1*10 5 CFU / mL-9*10 The bacteria are a mixture of one or more of Staphylococcus epidermidis and Micrococcus luteus; the solvent of the histidine solution is normal saline containing 0.15-1% of trypsin peptone; and the solvent of the bacterial suspension is normal saline containing 0.1-0.2% of trypsin soybean peptone liquid culture medium. The fabric yellowing reagent can be used for simulating fabric yellowing, and has good operability, reproducibility and data reliability.

The invention provides bacillus mojavensis and belongs to the technical field of microorganisms. The preservation number of the bacillus mojavensis VT275 is CGMCC (China General Microbiological Culture Collection Center) No.29974. The bacillus mojavensis VT275 can be used for effectively inhibiting common skin pathogenic bacteria and food-borne pathogenic bacteria, such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes, shigella, enterococcus faecalis and the like. The bacillus mojavensis VT275 disclosed by the invention can be used for preventing or treating skin diseases such as specific dermatitis or controlling food-borne infection, and has a good application prospect in the fields of medicines, cosmetics, edible microorganisms, feed microorganisms and the like.

The invention relates to a biomarker for individual recognition and application thereof, and relates to the technical field of biology. The biomarker comprises at least one of the following microorganisms: propionibacterium acnes, staphylococcus epidermidis, marine paracoccus, streptococcus, rhodococcus fence celebrating, staphylococcus, pseudomonas, streptococcus sanguineus, achromobacter xylosoxidans, acinetobacter calcoaceticus, acinetobacter johnsonii, staphylococcus lentus, pseudomonas toralaris and brevundimonas vesicularis. Or enterococcus faecium. The biomarker can provide analysis with higher resolution in the aspect of differential strain information, has a better distinguishing effect, higher accuracy and sensitivity on individual recognition, and can be used as a new technical means for supplementing forensic individual recognition.

The present invention relates to the field of biological fermentation application technology, and in particular, to use of a milk peptide fermentation product in regulating skin microecological balance. The milk peptide fermentation product selectively regulates the growth of Staphylococcus epidermidis and inhibits the growth of Staphylococcus aureus and Escherichia coli. It was discovered for the first time that the milk peptide fermentation product has a selective bacteriostatic effect on skin microorganisms. The experimental results show that the milk peptide fermentation product has an inhibitory effect on Escherichia coli and Staphylococcus aureus, but has no effect on the normal growth of Staphylococcus epidermidis. This characteristic is obviously different from common broad-spectrum chemical bacteriostatic agents, and the use of the milk peptide fermentation product is more conducive to maintaining the balance of skin microbiota.

The invention provides an application of GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection, and the GSK2018682 has a CAS number of 1034688-30-6. The invention also provides an application of the GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection. According to the technical scheme, the novel medical application of the GSK2018682 is disclosed, and the GSK2018682 has good antibacterial activity and anti-biofilm activity on various gram-positive bacteria and can inhibit growth of staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, enterococcus faecium and the like and formation of biofilms.

The invention provides a beta-diketoamide compound and application thereof in preparation of a gram infection resistant drug, the structural formula of the beta-diketoamide compound is as shown in formula (1), in the formula (1), R1 is H or halogen; r2 is nitro, alkyl, halogen or methoxyl. The beta-diketoamide compound disclosed by the invention comprises gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis, enterococcus faecium and staphylococcus epidermidis and other clinical isolates, and shows antibacterial activity; after being combined with polymyxin, the compound has synergistic bacteriostatic activity on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli and pseudomonas aeruginosa, and can remove biofilms formed by staphylococcus aureus and enterococcus faecalis.

The application discloses a composition capable of effectively inhibiting the growth of Staphylococcus aureus biofilm. The application firstly optimizes the nitrogen source in the culture medium of Staphylococcus epidermidis CCSM0287 strain, fully explores the growth difference of Staphylococcus epidermidis under different culture media and culture conditions and the inhibition effect of the fermentation supernatant on Staphylococcus aureus biofilm, then compounds the fermentation supernatant of Staphylococcus epidermidis CCSM0287 obtained by using the optimized culture medium (the nitrogen source adopts tryptone + soybean peptone + fresh beef bone collagen peptide powder) with the fermentation supernatant of Lactobacillus paracasei S20, can obviously inhibit the growth of Staphylococcus aureus biofilm and destroy the surface structure of the Staphylococcus aureus biofilm, and can be applied in bacteriostatic products.

The present invention discloses a visible light-responsive photocatalytic antibacterial material and a preparation method thereof, and its chemical formula is: Ag2TaNb 7‑7x V 7x O 21 , where x is the molar number of vanadium ions V 5+ substituting niobium ions Nb 5+ , and 0 ≤ x ≤ 0.07. The partial substitution of niobium ions Nb 5+ by vanadium ions V 5+ in the lattice causes the optical cut-off light absorption edge of the material to redshift, broadening the light absorption wavelength range of the material in the visible light region; at the same time, the lattice perturbation brought about by doping also improves the separation efficiency of photo-generated charges, not only further enhancing the photocatalytic performance, but also broadening the light response range, achieving a significant improvement in the antibacterial effect under visible light irradiation. The preparation method of the material of the present invention is simple and easy to implement, the raw materials are easily available, the cost is low, the preparation method is pollution-free, its photocatalytic antibacterial activity is high, and it has good application prospects in the antibacterial inactivation of Escherichia coli and Staphylococcus epidermidis.

A bithionol derivative, and a preparation method therefor and a use thereof. The bithionol derivative is as represented by any one of chemical structural formulas I-1 to I-7. The bithionol derivative as represented by the structural formula exhibits better bacteriostatic activity against clinical isolates of gram-positive bacteria such as Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Staphylococcus epidermidis and the effect of inhibiting the formation of Staphylococcus aureus biofilms. As compared with bithionol and other bithionol derivatives, the bithionol derivative as represented by the structural formula has a lower inhibitory concentration, a better antibacterial effect, and potential application value in clinical antibacterial infection treatment.

The invention discloses staphylococcus albus and application thereof in fermentation of high-salt liquid-state clean label soy sauce. Belongs to the technical field of food fermentation. The staphylococcus fish fermenti CS1.22 is separated from soy sauce mash for the first time, and an application example of the staphylococcus fish fermenti CS1.22 in high-salt liquid-state clean label soy sauce is not reported yet at present. The strain can effectively inhibit bacillus causing deterioration of soy sauce, the bacteriostatic effect of the strain is mainly non-acid bacteriostasis, the bacteriostatic action pH range is 4.0-5.0, the strain is suitable for being applied to soy sauce fermentation, and the total number of bacterial colonies of finished soy sauce can be effectively reduced; when the high-salt liquid-state soy sauce is added to the fermentation of the high-salt liquid-state soy sauce, the content of volatile flavor substances can be remarkably increased while the content of amino acid nitrogen is increased, so that the high-salt liquid-state'clean label 'soy sauce is rich in flavor and excellent in quality.

The invention discloses a preparation method and application of a composite antibody IgY for preventing and treating acne, and belongs to the technical field of cosmetics. The preparation method comprises the following steps: (1) preparing immunogens: respectively mixing inactivated propionibacterium acnes liquid, staphylococcus epidermidis liquid, staphylococcus aureus liquid and escherichia coli liquid with an ISA 78 adjuvant to obtain the immunogens of the four bacteria; (2) immunizing: respectively injecting immunogens of the four bacteria to laying hens, and collecting to obtain immunized eggs of the four bacteria; and (3) collection and preparation of a composite antibody IgY: mixing immunized eggs of the four bacteria, separating yolk, and carrying out acid treatment and impurity removal to obtain the composite antibody IgY. The prepared composite antibody IgY is high in titer, has the effect of preventing and treating acne and acne infection, is high in safety and remarkable in curative effect, and provides a new treatment strategy for preventing and treating acne.

The invention discloses an antibacterial peptide as well as a composition and application thereof, an amino acid sequence of the antibacterial peptide is shown as a formula I. The antibacterial peptide has a good antibacterial effect on methicillin staphylococcus aureus MRSA, methicillin-sensitive staphylococcus aureus MSSA and methicillin-resistant staphylococcus epidermidis MRSE, and the antibacterial peptide has a good antibacterial effect on methicillin-sensitive staphylococcus aureus MRSA, methicillin-sensitive staphylococcus aureus MSSA and methicillin-resistant staphylococcus epidermidis MRSE. The antibacterial peptide and the pharmaceutical composition prepared by adding auxiliary materials are expected to be widely applied to preparation of drugs for controlling or preventing microbial infection.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention belongs to the technical field of probiotics, and particularly relates to plant lactobacillus with bacteriostatic activity and application of the plant lactobacillus. Wherein the plant lactobacillus with bacteriostatic activity is separated from the intestinal tract of a healthy human body, and the LV1000 fermentation filtrate freeze-dried powder is prepared through fermentation, centrifugation, filtration, ultrafiltration concentration and vacuum freeze-drying by taking inactivated staphylococcus epidermidis bacterial suspension as an inducer through a specific induction fermentation culture medium. Meanwhile, the freeze-dried powder is compounded with an embedding compound, galactooligosaccharide, beta-cyclodextrine, erythritol and the like, so that the fermented beverage capable of improving the intestinal microecology is prepared. The freeze-dried powder of the LV1000 fermentation filtrate can specifically inhibit enteropathogenic bacteria, the tea polyphenol in the embedded compound can further synergistically enhance the bacteriostatic action and exert the antioxidant effect, and the fermented beverage which is high in stability, fine and smooth in taste, free of refrigeration and capable of being directly drunk and improving the intestinal microecology is prepared.

To provide a composition effective for treating microbial skin infections, atopic dermatitis and the like.SOLUTION: Methods and compositions comprising hogocidin peptides (SH-lantibiotics), derivatives and variants are provided. Also provided are methods and compositions, including probiotic compositions, that utilize strains of Staphylococcus hominis and Staphylococcus epidermidis that produce hogocidin, hogocidin-like peptides, or other inhibitors of skin pathogens. Methods of treating microbial skin infections and atopic dermatitis are also provided.SELECTED DRAWING: Figure 1A-B

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 9I and 16F replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-11. Compared to the template peptide PL-0, the stapling peptide PL-11 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.